Procter & Gamble Co. has agreed to acquire supplement maker Thorne for $3.8 billion, a transaction that the company plans to announce later today, CEO Shailesh Jejurikar said during a Tuesday appearance on CNBC.
Jejurikar indicated the purchase is part of P&G's broader push to grow its beauty and wellness businesses through strategic acquisitions. He revealed the pending deal while speaking about the company's expansion plans on national television.
Thorne, established in 1984, makes a variety of nutritional products spanning categories such as creatine supplements and prenatal vitamins. The brand was taken private in 2023 when L Catterton, a private equity firm with backing from luxury goods group LVMH, acquired the company for $680 million.
The supplement maker has been the subject of acquisition speculation for several months. Media reports earlier this year named UK-based Haleon Plc and Unilever Plc among the potential suitors that had been linked to Thorne.
Separately, CNBC reported that Thorne was on track to generate about $650 million in total sales in 2026, according to information disclosed earlier in the year. That sales trajectory was referenced in coverage of the company as bidders and strategists considered Thorne's market position.
The announced $3.8 billion price tag reflects P&G's move into the wellness segment through an established supplement brand. Details about financing, regulatory review, or the transaction's expected close date were not disclosed during the CEO's remarks and are pending the formal announcement.
Context and implications
- P&G's stated acquisition objective is to expand its beauty and wellness portfolio - a strategic area the company has highlighted for growth.
- Thorne's product range and its private equity ownership since 2023 were cited as background to the deal.
- Competing interest from other large consumer-health companies was reported earlier in the year, underscoring the strategic value of the supplement business.